Cannabis acts on one of the brain’s most widely distributed signaling systems, which is why its effects can reach perception, memory, mood, appetite, pain, movement, sleep, and reward. Most neuroscience has focused on delta-9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD. THC produces the characteristic intoxication associated with marijuana, while CBD has a different pharmacology and does not produce the same high.
The neuroscience of cannabis is neither a story of a harmless plant nor one of inevitable brain damage. Effects depend on dose, potency, age, frequency, cannabinoid balance, genetics, mental health, and previous exposure. Acute intoxication, long-term adaptation, medical use, and cannabis use disorder involve overlapping but distinct processes.
The Endocannabinoid System
Cannabis affects the brain because the nervous system already contains an internal cannabinoid network. The endocannabinoid system includes CB1 and CB2 receptors, the signaling molecules anandamide and 2-arachidonoylglycerol, and enzymes that create and break down those molecules. CB1 receptors are abundant in the cortex, hippocampus, basal ganglia, cerebellum, and regions involved in memory, decision-making, movement, emotion, and reward. CB2 receptors are more strongly associated with immune signaling, although they also appear in the nervous system.
Endocannabinoids usually function as short-range regulators of synaptic communication. They are often produced by a receiving neuron and travel backward across the synapse, temporarily reducing neurotransmitter release from the sending neuron. THC enters this system from outside the body and activates CB1 receptors more broadly and for longer than endocannabinoids normally do, disrupting the precise timing that makes the system useful.
How THC Alters Neural Communication
THC is a partial agonist at CB1 receptors. Because these receptors sit mainly on presynaptic terminals, THC can alter the release of GABA, glutamate, and other neurotransmitters across many brain circuits. Rather than switching on a single “cannabis center,” it changes the balance of excitation and inhibition in systems regulating attention, sensory processing, emotional salience, memory, and motor control.
Human imaging supports this distributed model. Reviews find that THC changes activity in the medial temporal lobe, prefrontal cortex, striatum, amygdala, cerebellum, and related networks. In a placebo-controlled fMRI study, Matthijs Bossong and colleagues found that inhaled THC altered activity during memory encoding and recall, including within medial temporal and prefrontal regions. This helps explain why intoxication can change not only what a person remembers, but how information is organized and retrieved.
Memory, Attention, and Time Perception
The hippocampus contains many CB1 receptors and is central to forming new episodic memories. Acute THC commonly weakens the encoding of new information, making it harder to hold a conversation in sequence, remember recent instructions, or preserve the context around an event. Working memory can also be disrupted when a task requires tracking several pieces of information while resisting distraction. These effects generally become stronger as the dose rises.
THC also changes attention and the subjective structure of time. Ordinary stimuli may feel unusually vivid or meaningful, while divided attention becomes less reliable. Time may seem slowed because more attention is directed toward immediate sensations and memory stores the sequence of events less efficiently. The experience can feel expansive, but the same changes can impair driving, complex decisions, and tasks that depend on accurate timing.
Reward, Emotion, and Dopamine
Cannabis does not stimulate dopamine as directly or powerfully as cocaine or amphetamine. THC influences dopamine indirectly through cannabinoid receptors on circuits that regulate dopamine-producing neurons. Human PET studies have produced mixed findings, with some detecting modest dopamine release in parts of the striatum and others finding little significant change. A systematic review concluded that the acute dopaminergic response is smaller and less consistent than the phrase “dopamine rush” suggests.
The emotional effects of THC may depend less on simple pleasure than on changes in salience, the brain’s judgment of what deserves attention and meaning. Music, food, humor, and social interactions may feel more compelling, but anxiety or suspicious ideas can also become unusually important. Sagnik Bhattacharyya and colleagues found that THC and CBD produced different, sometimes opposing patterns of brain activation during tasks involving memory, emotion, and sensory processing.
CBD and the Brain
CBD does not activate CB1 receptors in the same direct way as THC. It interacts with several targets, including serotonin 5-HT1A signaling, TRPV1 channels, adenosine pathways, and enzymes involved in endocannabinoid regulation. Researchers often describe CBD as polypharmacological because no single receptor accounts for all its effects. Human imaging suggests that CBD can alter networks involved in anxiety, memory, emotion, and psychosis-related processing, but results vary by dose and population.
CBD may moderate some THC effects under certain conditions, yet commercial claims often exceed the evidence. The interaction depends on the THC-to-CBD ratio, timing, route of administration, and total dose. A product containing a small amount of CBD beside a high concentration of THC should not automatically be considered protective. Clinical doses used in research are also often larger and more standardized than those found in consumer products.
Tolerance, Dependence, and Brain Adaptation
With repeated exposure, the brain adjusts to persistent CB1 receptor stimulation. Tolerance can develop as receptors become less available or less responsive, requiring a larger dose to produce familiar effects. Jussi Hirvonen and colleagues used PET imaging to study daily cannabis smokers and found reduced CB1 receptor availability in several brain regions. After approximately four weeks of monitored abstinence, receptor availability returned toward normal, showing that at least some cannabis-related adaptations are reversible.
Dependence can emerge when these adaptations become linked with learning, stress relief, and routine. During withdrawal, frequent users may experience irritability, restlessness, reduced appetite, sleep disturbance, vivid dreams, and craving. Cannabis use disorder therefore reflects both neuroadaptation and learned behavior. It is not simply weak discipline, nor does every regular user develop it.
Adolescence and the Developing Brain
Adolescence is a period of synaptic refinement, myelination, and maturation of circuits involved in judgment, emotional control, and planning. The endocannabinoid system participates in circuit formation and plasticity, creating a plausible reason why repeated high-THC exposure during development could have different effects than occasional adult use. Reviews have found associations between adolescent cannabis use and alterations in frontoparietal, frontolimbic, frontostriatal, and cerebellar systems.
Causality remains difficult to establish because adolescent users may differ from nonusers in alcohol or nicotine exposure, family environment, mental health, sleep, and risk-taking before cannabis use begins. Even so, the most consistent concerns involve early initiation, frequent use, high potency, and persistent consumption. A 2025 translational review concluded that converging animal and longitudinal human evidence supports particular caution with frequent high-THC use during adolescence.
Psychosis and Individual Vulnerability
THC can temporarily produce perceptual changes, suspiciousness, disorganized thinking, and anxiety even in healthy volunteers. Most users do not develop a psychotic disorder, but risk is not evenly distributed. It rises with heavier use, greater THC potency, earlier exposure, and personal or family vulnerability. In the multicenter EU-GEI study, daily use of high-potency cannabis was associated with substantially higher odds of first-episode psychosis than never using cannabis, although observational research cannot prove that cannabis caused every case.
These findings do not mean cannabis inevitably causes schizophrenia. Psychosis develops through interacting genetic, developmental, and environmental influences. Cannabis may function as one contributing exposure that brings symptoms forward, increases their probability, or worsens outcomes in susceptible people. Individuals with previous psychosis or a strong family history face a different risk calculation than the average adult user.
Therapeutic Neuroscience and Its Limits
The same system that makes cannabis psychoactive also makes cannabinoids medically interesting. Endocannabinoid signaling influences pain, nausea, appetite, muscle tone, seizure activity, sleep, and inflammation. Cannabinoid-based medicines have established roles in limited conditions, including certain treatment-resistant epilepsies, chemotherapy-related nausea, and some forms of spasticity or pain. These uses involve specific compounds, doses, and clinical goals rather than the assumption that cannabis treats every neurological disorder.
Therapeutic potential does not erase cognitive or psychiatric risk. A substance can provide symptom relief while also impairing memory, coordination, or attention. Evidence for one cannabinoid, formulation, or condition should not be transferred automatically to another. Neuroscience increasingly treats cannabis not as one uniform drug but as a family of exposures whose effects depend on chemistry, dose, delivery, and the biology of the person receiving them.
Understanding Cannabis and the Brain
Cannabis changes brain function by entering an existing regulatory system that helps control synaptic activity. THC disrupts the normal timing of that system, producing widespread changes in memory, attention, perception, reward, emotion, and movement. CBD acts through a broader collection of targets and may sometimes counter particular THC effects, but it is not a universal antidote.
The strongest conclusion is that cannabis effects exist on a continuum. Lower, infrequent doses in a healthy adult are neurologically different from daily exposure to high-potency concentrates during adolescence or in someone vulnerable to psychosis. Some adaptations can reverse with abstinence, while some risks become more significant with earlier and heavier use. Cannabis neuroscience supports neither exaggeration nor dismissal; it supports careful attention to dose, development, susceptibility, and sustained patterns of use.
